Literature DB >> 26206191

Activation of endplate nicotinic acetylcholine receptors by agonists.

Anthony Auerbach1.   

Abstract

The interaction of a small molecule made in one cell with a large receptor made in another is the signature event of cell signaling. Understanding the structure and energy changes associated with agonist activation is important for engineering drugs, receptors and synapses. The nicotinic acetylcholine receptor (AChR) is a ∼300kD ion channel that binds the neurotransmitter acetylcholine (ACh) and other cholinergic agonists to elicit electrical responses in the central and peripheral nervous systems. This mini-review is in two sections. First, general concepts of skeletal muscle AChR operation are discussed in terms of energy landscapes for conformational change. Second, adult vs. fetal AChRs are compared with regard to interaction energies between ACh and agonist-site side chains, measured by single-channel electrophysiology and molecular dynamics simulations. The five aromatic residues that form the core of each agonist binding site can be divided into two working groups, a triad (led by αY190) that behaves similarly at all sites and a coupled pair (led by γW55) that has a large influence on affinity only in fetal AChRs. Each endplate AChR has 5 homologous subunits, two of α(1) and one each of β, δ, and either γ (fetal) or ϵ (adult). These nicotinic AChRs have only 2 functional agonist binding sites located in the extracellular domain, at αδ and either αγ or αϵ subunit interfaces. The receptor undergoes a reversible, global isomerization between structures called C and O. The C shape does not conduct ions and has a relatively low affinity for ACh, whereas O conducts cations and has a higher affinity. When both agonist sites are empty (filled only with water) the probability of taking on the O conformation (PO) is low, <10(-6). When ACh molecules occupy the agonist sites the C→O opening rate constant and C↔O gating equilibrium constant increase dramatically. Following a pulse of ACh at the nerve-muscle synapse, the endplate current rises rapidly to reach a peak that corresponds to PO ∼0.96.
Copyright © 2015. Published by Elsevier Inc.

Entities:  

Keywords:  Acetylcholine; Allosteric; Binding; Gating; Neuromuscular; Nicotinic

Mesh:

Substances:

Year:  2015        PMID: 26206191      PMCID: PMC4600445          DOI: 10.1016/j.bcp.2015.06.024

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  28 in total

1.  Sources of energy for gating by neurotransmitters in acetylcholine receptor channels.

Authors:  Prasad Purohit; Iva Bruhova; Anthony Auerbach
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-30       Impact factor: 11.205

2.  Design and control of acetylcholine receptor conformational change.

Authors:  Snehal V Jadey; Prasad Purohit; Iva Bruhova; Timothy M Gregg; Anthony Auerbach
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-01       Impact factor: 11.205

3.  Functional anatomy of an allosteric protein.

Authors:  Prasad Purohit; Shaweta Gupta; Snehal Jadey; Anthony Auerbach
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

4.  Glycine hinges with opposing actions at the acetylcholine receptor-channel transmitter binding site.

Authors:  Prasad Purohit; Anthony Auerbach
Journal:  Mol Pharmacol       Date:  2010-11-29       Impact factor: 4.436

5.  Loop C and the mechanism of acetylcholine receptor-channel gating.

Authors:  Prasad Purohit; Anthony Auerbach
Journal:  J Gen Physiol       Date:  2013-03-11       Impact factor: 4.086

6.  Asymmetric transmitter binding sites of fetal muscle acetylcholine receptors shape their synaptic response.

Authors:  Tapan K Nayak; Anthony Auerbach
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-29       Impact factor: 11.205

7.  Function of interfacial prolines at the transmitter-binding sites of the neuromuscular acetylcholine receptor.

Authors:  Shaweta Gupta; Prasad Purohit; Anthony Auerbach
Journal:  J Biol Chem       Date:  2013-03-21       Impact factor: 5.157

8.  Action of nicotine and analogs on acetylcholine receptors having mutations of transmitter-binding site residue αG153.

Authors:  Snehal Jadey; Prasad Purohit; Anthony Auerbach
Journal:  J Gen Physiol       Date:  2013-01       Impact factor: 4.086

9.  An integrated catch-and-hold mechanism activates nicotinic acetylcholine receptors.

Authors:  Snehal Jadey; Anthony Auerbach
Journal:  J Gen Physiol       Date:  2012-07       Impact factor: 4.086

10.  Molecular recognition of the neurotransmitter acetylcholine by an acetylcholine binding protein reveals determinants of binding to nicotinic acetylcholine receptors.

Authors:  Jeppe A Olsen; Thomas Balle; Michael Gajhede; Philip K Ahring; Jette S Kastrup
Journal:  PLoS One       Date:  2014-03-17       Impact factor: 3.240

View more
  5 in total

1.  Dose-Response Analysis When There Is a Correlation between Affinity and Efficacy.

Authors:  Anthony Auerbach
Journal:  Mol Pharmacol       Date:  2015-12-11       Impact factor: 4.436

2.  Muscle Nicotinic Acetylcholine Receptors May Mediate Trans-Synaptic Signaling at the Mouse Neuromuscular Junction.

Authors:  Xueyong Wang; J Michael McIntosh; Mark M Rich
Journal:  J Neurosci       Date:  2018-01-11       Impact factor: 6.167

3.  Human PLD structures enable drug design and characterization of isoenzyme selectivity.

Authors:  Claire M Metrick; Emily A Peterson; Joseph C Santoro; Istvan J Enyedy; Paramasivam Murugan; TeYu Chen; Klaus Michelsen; Michael Cullivan; Kerri A Spilker; P Rajesh Kumar; Tricia L May-Dracka; Jayanth V Chodaparambil
Journal:  Nat Chem Biol       Date:  2020-02-10       Impact factor: 15.040

Review 4.  Homeostatic synaptic plasticity at the neuromuscular junction in myasthenia gravis.

Authors:  Xueyong Wang; Mark M Rich
Journal:  Ann N Y Acad Sci       Date:  2017-10-05       Impact factor: 5.691

Review 5.  Controversies in Ocular Myasthenia Gravis.

Authors:  Amelia Evoli; Raffaele Iorio
Journal:  Front Neurol       Date:  2020-11-30       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.